Vnitr Lek 2020, 66(1):10-14 | DOI: 10.36290/vnl.2020.002

Treatment of arterial hypertension in metabolic syndrome

Barbora Nussbaumerová
1 Centrum preventivní kardiologie, Univerzita Karlova, Lékařská fakulta v Plzni . interní klinika Fakultní nemocnice Plzeň

High-normal blood pressure/arterial hypertension is one of the diagnostic criteria of metabolic syndrome. Metabolic syndrome is connected with an increased cardiometabolic risk. The cornerstone of treatment is lifestyle intervention. Pharmacotherapy is iniciated with ACE inhibitors/angiotensin receptor blockers and calcium chanel blockers or diuretic according to current guidelines.

Keywords: metabolic syndrome, arterial hypertension, lifestyle intervention, pharmacotherapy, target values.

Published: February 21, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. Treatment of arterial hypertension in metabolic syndrome. Vnitr Lek. 2020;66(1):10-14. doi: 10.36290/vnl.2020.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the Metabolic Syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645. Go to original source... Go to PubMed...
    2. Cífková R, Bruthans J, Adámková V, et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech postMONICA. Cor Vasa 2011; 53: 220-229. Go to original source...
    3. Rosolová H. Metabolický syndrom a jeho význam v primární prevenci nemocí s častým výskytem v populaci. Cor Vasa 2011; 53: 249-252. Go to original source...
    4. Hamet P, Merlo E, Šeda O et al. Quantitative Founder‑Effect Analysis of French Canadian Families Identifies Specific Loci Contributing to Metabolic Phenotypes of Hypertension. Am J Hum Genet 2005; 76: 815-832. Go to original source... Go to PubMed...
    5. Reaven GM, Lithell L, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381. Go to original source... Go to PubMed...
    6. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal (2018) 39, 3021-3104 doi:10.1093/eurheartj/ehy339. Go to original source... Go to PubMed...
    7. Stevens VJ, Obarzanek E, Cook NR et al. Trials for the Hypertension Prevention Research G. Long term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1-11. Go to original source... Go to PubMed...
    8. Elliott P, Stamler J, Nichols R et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ 1996; 312: 1249-1253. Go to original source... Go to PubMed...
    9. Widimský J, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze, kardiovaskulární prevence 2018; 7 (Supplementum): 1-20.
    10. Bakris G, Molitch M, Hewkin A et al.: Differences in glucose tolerance between fixed‑dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-2597. Go to original source... Go to PubMed...
    11. Egan BM, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59: 1124-1131. Go to original source... Go to PubMed...
    12. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two‑drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28: 1584-1590. Go to original source... Go to PubMed...
    13. Conn VS, Ruppar TM, Chase JA et al. Interventions to improve medication adherence in hypertensive patients: systematic review and meta‑analysis. Curr Hypertens Rep 2015;17: 94. Go to original source... Go to PubMed...
    14. Mancia G, Rea F, Cuspidi C et al. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens 2017; 35: 225-233. Go to original source... Go to PubMed...
    15. The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood‑Pressure Control. N Engl J Med 2015; 373:2103-2116 DOI: 10.1056/NEJMoa1511939 Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.